Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Harrington

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
British Journal of Haematology|July 8, 2022
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotypePatrick Harrington, Richard Dillon, Deepti Radia, et al.
Hepatology (Baltimore, Md.)|May 22, 2012
Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjectsJeffry Florian, Pravin R Jadhav, Shashi Amur, et al.
Bone|June 23, 2009
Identification of differentially expressed genes between osteoblasts and osteocytesFrane Paic, John C Igwe, Ravi Nori, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Antiviral Research|September 28, 2021
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's EvaluationKirk Chan-Tack, Patrick Harrington, Timothy Bensman, et al.
British Journal of Haematology|March 22, 2021
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centrePaul Deschamps, Mufaddal Moonim, Deepti Radia, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
Genes|February 27, 2026
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage ModelAndrea Duminuco, Silvia Rita Vitale, Antonella Nardo, et al.
British Journal of Haematology|March 15, 2021
Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Patrick Harrington, Claire N Harrison, Richard Dillon, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|July 8, 2022
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotypePatrick Harrington, Richard Dillon, Deepti Radia, et al.
Hepatology (Baltimore, Md.)|May 22, 2012
Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjectsJeffry Florian, Pravin R Jadhav, Shashi Amur, et al.
Bone|June 23, 2009
Identification of differentially expressed genes between osteoblasts and osteocytesFrane Paic, John C Igwe, Ravi Nori, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Antiviral Research|September 28, 2021
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's EvaluationKirk Chan-Tack, Patrick Harrington, Timothy Bensman, et al.
British Journal of Haematology|March 22, 2021
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centrePaul Deschamps, Mufaddal Moonim, Deepti Radia, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
Genes|February 27, 2026
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage ModelAndrea Duminuco, Silvia Rita Vitale, Antonella Nardo, et al.
British Journal of Haematology|March 15, 2021
Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Patrick Harrington, Claire N Harrison, Richard Dillon, et al.
Pageof 5